Form 4: BioAge Labs CMO Rubin Granted 110,000 Stock Options

BioAge Labs' Chief Medical Officer, Paul D. Rubin, was granted 110,000 stock options with an exercise price of $19.63, vesting monthly over four years.

Summary

• Paul D. Rubin, the Chief Medical Officer of BioAge Labs, Inc. (BIOA), acquired 110,000 stock options.
• The transaction date for this grant was February 17, 2026.
• Each option has an exercise price of $19.63.
• The options vest as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2026, and subsequent tranches vesting on the monthly anniversary thereafter.
• Vesting is contingent upon Mr. Rubin's continued service to BioAge Labs, Inc.
• The options have an expiration date of February 16, 2036.
• Following this transaction, Mr. Rubin beneficially owns 110,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at retaining key talent and aligning management interests with long-term shareholder value. It does not indicate immediate financial performance but signals stability in executive leadership.

Positives

• The grant of stock options aligns the Chief Medical Officer's long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedule encourages continued service and commitment from a key executive.

Future Outlook

The vesting schedule for the stock options extends over four years, indicating an expectation of continued service from the Chief Medical Officer and a long-term incentive structure.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like a Chief Medical Officer is a standard practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to attract, retain, and motivate top talent by linking their personal financial success to the company's long-term share price performance. It is a common mechanism for aligning executive incentives with shareholder value creation, particularly in companies with significant research and development pipelines like BioAge Labs.

Comparison to Industry Standards

• The grant of 110,000 stock options to a Chief Medical Officer is within the typical range for executive compensation in early-stage or growth-oriented biotech companies, comparable to grants seen at companies like Recursion Pharmaceuticals or Denali Therapeutics for similar roles, depending on company size and stage.
• The four-year monthly vesting schedule is a standard industry practice, promoting long-term commitment and retention, similar to vesting schedules observed at companies such as Moderna or BioNTech for their executive teams.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Medical Officer's financial incentives with the company's long-term performance, potentially benefiting shareholders if the stock price increases.
• Employees: This grant is specific to a key executive and does not directly impact the broader employee base, though it may signal confidence in leadership.

Next Steps

• The stock options will continue to vest monthly over the next four years, subject to the Chief Medical Officer's continued employment.

Key Dates

Keywords

BioAge Labs, BIOA, Stock Options, Insider Transaction, Form 4, Chief Medical Officer, Executive Compensation, Equity Grant, Paul D. Rubin